Drug Profile
Research programme: mono-specific IGFBP inhibitors - OncoGenex
Alternative Names: OGX 2252; OGX 2255Latest Information Update: 03 Mar 2009
Price :
$50
*
At a glance
- Originator OncoGenex Technologies
- Developer OncoGenex Pharmaceuticals
- Class Oligonucleotides
- Mechanism of Action Insulin-like growth factor binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Mar 2009 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
- 14 Mar 2003 Preclinical trials in Cancer in Canada (unspecified route)